Advancing endogenous ADAR-mediated RNA editing through pharmaceutical collaboration

FREST welcomes collaborations with pharmaceutical companies to advance guide RNA-based RNA-editing therapeutics. Our platform recruits endogenous ADAR to edit disease-relevant mRNA, enabling programmable A-to-I RNA editing without permanent genome modification or exogenous editing enzymes.

Why FREST

FREST is developing an endogenous ADAR-mediated RNA editing platform designed to enable programmable A-to-I editing of disease-relevant mRNA. Our approach combines guide RNA-based oligonucleotide design with delivery optimization and disease-focused target selection.

How we collaborate

We welcome discussions with pharmaceutical partners seeking to explore RNA editing as a therapeutic modality. Potential collaboration topics include target selection, guide RNA design, delivery optimization, in vivo proof-of-concept, and disease-area expansion.

Pipeline opportunities

FREST is advancing RNA-editing therapeutic programs for genetically defined diseases, including inherited macular dystrophy and other rare or disease-focused indications.

Let's discuss collaboration

We welcome discussions with pharmaceutical partners on target selection, guide RNA design, delivery optimization, in vivo proof-of-concept, disease-area expansion, licensing, and co-development.